NCT04140162 · OUTCOME

Incidence of Treatment-emergent Adverse Events

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy · Source last updated 2026-07-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From start of study treatment (Dara-Rd) up to 30 days post last dose of study treatment (Dara, R, V or d)

What was measured

Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
reporting Status: NOT_POSTED
time Frame: From start of study treatment (Dara-Rd) up to 30 days post last dose of study treatment (Dara, R, V or d)
title: Incidence of Treatment-emergent Adverse Events
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice